Actively Recruiting
Study Comparing Rivaroxaban and Warfarin to Prevent Blood Clots in Children Over 2 Years Old with Giant Coronary Artery Aneurysms After Kawasaki Disease
Led by Children's Hospital of Fudan University · Updated on 2026-07-06
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring the use of rivaroxaban compared to warfarin for blood clot prevention in children over 2 years old with giant coronary artery aneurysms following Kawasaki disease. This condition requires lifelong anticoagulant treatment, which can be challenging for patients and families. The study aims to assess the feasibility, safety, and effectiveness of a specially adjusted dosing plan for rivaroxaban designed for Chinese children. Participants will be randomly assigned in a 21 ratio to receive either rivaroxaban plus an antiplatelet drug aspirin or clopidogrel or warfarin plus an antiplatelet drug, both treatments lasting for 3 months. Warfarin dosing will be adjusted monthly to maintain a specific blood clotting range. The study is open-label and conducted across multiple centers, focusing on a 15 mg-equivalent dosing regimen for rivaroxaban. Throughout the study, researchers will monitor participants for new blood clots, bleeding events, heart-related adverse events, and treatment adherence. They will collect data on blood drug levels, clotting activity, changes in coronary artery aneurysms, and any side effects. The main outcome is measured from treatment start to three months, with careful safety and effectiveness assessments over this period. The study plans to enroll 100 children and is sponsored by Childrens Hospital of Fudan University.
CONDITIONS
Brief Title
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
Research Team
F
Fang Liu, MD
G
Guangan Dai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here